Stem cells show extraordinary potential to treat various cancers Print E-mail
By Staff and Wire Reports   
Wednesday, 10 March 2010 11:22

Could latest results mean that IMUC is close to securing a partnership? ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC) announced today that its dendritic cell-based vaccination with cancer stem cells (CSCs) demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.


CEO, Dr. Manish Singh told BioMedReports: “We believe this data, while received from animal studies, provides compelling evidence that cancer stem cells have extraordinary potential to treat various cancers. There were many promising markers,  including increased Gamma-Interferon levels in animals treated with CSCs, which suggest an increased immune response which is consistent with increased survival outcomes. We are excited about moving this into the clinic, as other companies have entered into partnerships with major pharmaceutical companies on less compelling data from animal studies."

According to the company, rats were either immunized with cancer stem cells (CSCs) from a brain cancer tumor or the daughter cells (the bulk of the tumor), and results showed that  that those immunized with the CSCs had a median survival of 50 days compared to 29 days for daughter cells. Furthermore, 30% of animals vaccinated against cancer stem cells demonstrated long term survival as compared to animals vaccinated with the bulk of the tumor, all of which died.

“We are excited by the study’s results, as it represents a significant step forward in the continued development of our cancer stem cell based vaccines,” said Dr. Manish Singh , PhD., President and CEO of ImmunoCellular Therapeutics.  “The data further validates our research indicating that targeting CSCs has the potential to be a highly effective method of treating various cancers.”  The data also demonstrated increased Gamma-Interferon levels in animals treated with CSCs, indicating an increased immune response consistent with increase in survival further supporting the mechanism of action of this approach.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter